Venclyxto Gets EU Nod – But Won't Be A Humira Replacement For AbbVie Yet

 
• By Lucie Ellis-Taitt

AbbVie and Genentech's chronic lymphocytic leukemia (CLL) drug Venclyxto has been recommended for conditional approval in Europe, but its initial limited patient population and potential reimbursement troubles won't see it replace top-seller Humira as a growth driver for AbbVie.

More from New Products

More from Scrip